Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (261-270 of 584) with videos related to

Pageof 59
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemiaJorge E Cortes, Dan Jones, Susan O'Brien, et al.
Journal of Hematology & Oncology|October 16, 2020
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemiaJorge E Cortes, Marcos de Lima, Hervé Dombret, et al.
Cancer|April 17, 2014
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutationsYesid Alvarado, Hagop M Kantarjian, Rajyalakshmi Luthra, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemiaFrancis J Giles, Gary Guangping Shi, Jorge E Cortes, et al.
Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.
Haematologica|October 19, 2010
Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasGautam Borthakur, Hagop Kantarjian, Farhad Ravandi, et al.
Blood Cancer Journal|February 4, 2017
Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemiaZ Chen, L J Medeiros, H M Kantajian, et al.
Experimental Hematology & Oncology|November 21, 2017
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)Lucia Masarova, C Cameron Yin, Jorge E Cortes, et al.
British Journal of Haematology|March 8, 2007
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictorsGautam Borthakur, Susan O'Brien, William G Wierda, et al.
Cancer|July 11, 2008
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitorsDan Jones, Deborah Thomas, C Cameron Yin, et al.
Pageof 59

Showing results (261-270 of 584) with videos related to

Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemiaJorge E Cortes, Dan Jones, Susan O'Brien, et al.
Journal of Hematology & Oncology|October 16, 2020
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemiaJorge E Cortes, Marcos de Lima, Hervé Dombret, et al.
Cancer|April 17, 2014
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutationsYesid Alvarado, Hagop M Kantarjian, Rajyalakshmi Luthra, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemiaFrancis J Giles, Gary Guangping Shi, Jorge E Cortes, et al.
Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.
Haematologica|October 19, 2010
Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasGautam Borthakur, Hagop Kantarjian, Farhad Ravandi, et al.
Blood Cancer Journal|February 4, 2017
Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemiaZ Chen, L J Medeiros, H M Kantajian, et al.
Experimental Hematology & Oncology|November 21, 2017
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)Lucia Masarova, C Cameron Yin, Jorge E Cortes, et al.
British Journal of Haematology|March 8, 2007
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictorsGautam Borthakur, Susan O'Brien, William G Wierda, et al.
Cancer|July 11, 2008
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitorsDan Jones, Deborah Thomas, C Cameron Yin, et al.
Pageof 59